Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azacitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacitidine SCHEMBL169369 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL17537438 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL706302 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL20143987 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL10024703 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL13390797 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL23815524 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL19996985 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Fazarabine SCHEMBL3278 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL7146234 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149821-A1 | TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND VENETOCLAX/AZACITIDINE | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-11793802-B2 | Treatment of acute myeloid leukemia (AML) with venetoclax failure | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | FORTY SEVEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230330086-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-11660297-B2 | Antiproliferative compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230057071-A1 | COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230058489-A1 | COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2009147549-A1 | THERAPY DELIVERY AND MONITORING USING A GENE OF INTEREST-REPORTER FUSION PROTEIN AND OPTICAL IMAGING | KONINKLIJKE PHILIPS ELECTRONICS N. V. (NL) | 2009-12-10 | — | — | WO | disclosed |
| EP-2128259-A1 | Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging | Koninklijke Philips Electronics N.V. (NL) | 2009-12-02 | — | — | EP | disclosed |
| EP-2114152-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | Nevada Cancer Institute (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057071-A1 | COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | CD274, DDIT3, PDCD1 | DNMT1 416/4885LMNA 398/4885MTOR 1322/4885 |
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | CD47, MCL1, MYADM | DNMT1 13/4885LMNA 1824/4885MTOR 1710/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | DNMT1 101/4885LMNA 1335/4885MTOR 170/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | DNMT1 403/4885LMNA 1285/4885MTOR 4777/4885 |
| US-11660297-B2 | Antiproliferative compounds and second active agents for combined use | NEK4, NEK1, AURKB | DNMT1 170/4885LMNA 523/4885MTOR 61/4885 |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | HAVCR2, EIF2AK2, IKZF3 | DNMT1 1794/4885LMNA 3236/4885MTOR 4506/4885 |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | HAVCR2, EIF2AK2, IKZF3 | DNMT1 1794/4885LMNA 3236/4885MTOR 4506/4885 |
| US-11793802-B2 | Treatment of acute myeloid leukemia (AML) with venetoclax failure | MCL1, DNMT3A, NSD1 | DNMT1 20/4885LMNA 3339/4885MTOR 2478/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | DNMT1 202/4885LMNA 1278/4885MTOR 53/4885 |
| US-20230058489-A1 | COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA | MCL1, HAVCR2, BST2 | DNMT1 66/4885LMNA 2210/4885MTOR 2831/4885 |
| US-20230330086-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | DNMT1 100/4885LMNA 920/4885MTOR 53/4885 |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | DCTD, DNMT3A, HDAC5 | DNMT1 5/4885LMNA 939/4885MTOR 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.